Literature DB >> 27164064

Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders.

Lisa M Madden1, Robert J Hayashi1, Ka Wah Chan2, Michael A Pulsipher3, Dorothea Douglas4, Gregory A Hale5, Sonali Chaudhury6, Paul Haut7, Kimberly A Kasow8, Andrew L Gilman9, Lisa M Murray1, Shalini Shenoy10.   

Abstract

Reduced-intensity conditioning (RIC) before hematopoietic stem cell transplantation (HCT) in children could result in fewer complications during follow-up compared with myeloablative regimens. Hence, many RIC regimens are under investigation, but long-term follow-up is essential. We describe late follow-up beyond 2 years post-HCT in 43 children with nonmalignant disorders who underwent related or unrelated donor (56%) HCT on a multicenter study using a RIC regimen (alemtuzumab, fludarabine, and melphalan) followed by bone marrow (n = 30), peripheral blood (n = 3), or umbilical cord blood (n = 10) HCT for immune dysfunction, bone marrow failure, metabolic disorders, or hemoglobinopathy. Recipients (median age, 7.5 years; range, 3 to 26) underwent HCT 2 to 8 years (median, 3.1 years) before this report. Full donor (67%) or stable mixed chimerism (33%) was noted without late graft rejection. Five patients (12%) required systemic immunosuppression therapy (IST) beyond 2 years post-HCT for graft-versus-host disease (GVHD); 2 patients died 38 and 79 months later, whereas the others improved, enabling an IST wean. Overall, 17 complications were documented in 10 patients (23%). Complications not related to GVHD included hypothyroidism (n = 2), low grade neoplasms (n = 2), and delayed puberty (n = 1). One patient with GVHD had ovarian failure; all other postpubertal females resumed normal ovarian function. Twenty-seven of 28 school-age recipients were functioning at grade level. RIC HCT recipients thus had few regimen-related toxicities during long-term follow-up. However, objective long-term follow-up is still necessary to identify complications so timely intervention may be planned.
Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Childhood nonmalignant disorders; Late complications; Reduced-intensity conditioning; Stem cell transplantation

Mesh:

Substances:

Year:  2016        PMID: 27164064     DOI: 10.1016/j.bbmt.2016.04.025

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  7 in total

Review 1.  Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.

Authors:  Gregory M T Guilcher; Tony H Truong; Santosh L Saraf; Jacinth J Joseph; Damiano Rondelli; Matthew M Hsieh
Journal:  Semin Hematol       Date:  2018-04-25       Impact factor: 3.851

2.  Alternative donor hematopoietic stem cell transplantation for sickle cell disease.

Authors:  Andrew L Gilman; Michael J Eckrich; Stacy Epstein; Carrie Barnhart; Mark Cannon; Tracy Fukes; Michelle Hyland; Krishna Shah; Darci Grochowski; Elizabeth Champion; Anastasia Ivanova
Journal:  Blood Adv       Date:  2017-06-28

3.  High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS).

Authors:  Hisanori Fujino; Hiroyuki Ishida; Akihiro Iguchi; Masaei Onuma; Koji Kato; Mariko Shimizu; Masahiro Yasui; Hiroyuki Fujisaki; Kazuko Hamamoto; Kana Washio; Hirotoshi Sakaguchi; Emiko Miyashita; Yuko Osugi; Etsuko Nakagami-Yamaguchi; Akira Hayakawa; Atsushi Sato; Yoshiyuki Takahashi; Keizo Horibe
Journal:  Int J Hematol       Date:  2019-03-12       Impact factor: 2.490

4.  Influence of Mixed Chimerism on Outcome in Children With Anaemia After Haematopoietic Stem Cell Transplantation.

Authors:  Monika Lejman; Joanna Zawitkowska; Agnieszka Zaucha-Prażmo; Magdalena Cienkusz; Aleksandra Mroczkowska; Jerzy Kowalczyk; Katarzyna Drabko
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

5.  Reduced-intensity single-unit unrelated cord blood transplant with optional immune boost for nonmalignant disorders.

Authors:  Mark T Vander Lugt; Xiaohua Chen; Maria L Escolar; Beth A Carella; Jessie L Barnum; Randy M Windreich; Memphis J Hill; Michelle Poe; Rebecca A Marsh; Heather Stanczak; Elizabeth O Stenger; Paul Szabolcs
Journal:  Blood Adv       Date:  2020-07-14

Review 6.  Endocrinopathies in Inborn Errors of Immunity.

Authors:  Kei Takasawa; Hirokazu Kanegane; Kenichi Kashimada; Tomohiro Morio
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

7.  Primary immunosuppressive TNI-based conditioning regimens in pediatric patients treated with haploidentical hematopoietic cell transplantation.

Authors:  D Wegener; P Lang; F Paulsen; N Weidner; D Zips; M Ebinger; U Holzer; M Döring; F Heinzelmann
Journal:  Strahlenther Onkol       Date:  2021-09-02       Impact factor: 3.621

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.